Delhi-based DSS Imagetech and Tokyo’s CarbGem Inc. signed a strategic MOU on March 9, 2026, to deploy CarbGem’s award-winning AI solutions across Indian medical and research institutions, harnessing microscopy image data to tackle antimicrobial resistance and diagnostic challenges.
Glimpse:
Fresh off CarbGem’s “Top 10” nod at India’s AI Impact Summit 2026, the partnership leverages DSS’s nationwide imaging network to roll out AI for clinical diagnostics, research automation, and quality control, targeting hospitals, labs, and pharma amid booming demand for precision biotech tools.
DSS Imagetech Pvt. Ltd., a veteran New Delhi provider of microscopy, digital pathology, and molecular diagnostics since 1998, joined forces with CarbGem Inc. through a pivotal Memorandum of Understanding signed on March 9, 2026. CarbGem, a Shibuya-based innovator in AI-powered life science solutions, earned global acclaim as the sole Japanese firm among the “Top 10” startups at India’s AI Impact Summit 2026, selected from 4,650 applicants across 60+ countries for its healthcare diagnostic impact. This collaboration accelerates CarbGem’s India entry by tapping DSS’s established infrastructure partnerships with Evident (Olympus), Abbott, Agilent, and Takara Bio to distribute AI tools that analyze microscope and digital device images for real-world clinical and research applications. The move addresses India’s acute need for automated diagnostics in overburdened labs, where skilled shortages hinder timely results.
CarbGem’s regulatory-approved Software as a Medical Device (SaMD) excels in antimicrobial resistance (AMR) detection, rapid pathology analysis, and quality control standardization, processing vast image datasets to deliver evidence-based insights faster than manual methods. Integrated with DSS’s high-performance microscopes and lab automation, these solutions enable precise bacterial identification, drug efficacy predictions, and workflow efficiencies in IVF centers, pharmaceutical R&D, and hospital pathology. CarbGem’s tech, honed for global health challenges, now scales via DSS’s pan-India presence, promising 30-50% reductions in diagnostic turnaround times. Early deployments target urban research hubs and tier-2 labs, bridging urban-rural divides in biotech capabilities.
DSS’s expertise in research imaging, clinical diagnostics, and food testing complements CarbGem’s digital transformation platforms, creating end-to-end AI ecosystems from data capture to actionable intelligence. For clinicians, this means AI-assisted slide reviews slashing error rates; for researchers, automated GMO testing and molecular profiling; and for industries, DX tools combating AMR a crisis projected to claim 10 million lives annually by 2050 without intervention. The partnership extends beyond India to other emerging markets, fostering localized training and service support to ensure adoption. DSS’s joint ventures, like DSS-Takara Bio, provide ready pipelines for molecular integration, positioning the duo as leaders in AI-biotech fusion.
This alliance arrives amid India’s life sciences surge, with AI investments hitting record highs and government pushes for self-reliant medtech. It empowers institutions to tackle skilled labor gaps, regional disparities, and rising caseloads in infectious diseases and oncology. Future roadmaps include custom AI models trained on Indian datasets, mobile apps for field diagnostics, and collaborations with municipal health programs. By democratizing advanced tools, DSS-CarbGem accelerates innovation, potentially halving AMR-related costs and elevating India’s global biotech stature.
The MOU sparks job creation in AI deployment, data annotation, and field support, while bolstering supply chains for imaging hardware. As CarbGem eyes further SaMD approvals, this India foothold validates its tech for diverse populations, influencing strategies in Southeast Asia and Africa.
"This MOU propels our globally recognized AI into India's vibrant healthcare ecosystem unlocking faster diagnostics and AMR solutions for millions."
By
HB Team
Related News
